TITLE

Creatine treatment in muscle disorders: a meta-analysis of randomised controlled trials

AUTHOR(S)
Kley, R A; Tarnopolsky, M A; Vorgerd, M
PUB. DATE
April 2008
SOURCE
Journal of Neurology, Neurosurgery & Psychiatry;Apr2008, Vol. 79 Issue 4, p366
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article discusses a study that evaluated randomized controlled trials of creatine supplementation in hereditary muscle diseases. The study found that short and medium term creatine treatment improves muscle strength and increases lean body mass in patients with muscular dystrophies and that high dose creatine supplementation increased muscle pain in glycogenosis type V.
ACCESSION #
31609077

 

Related Articles

  • Anesthetic management of a child with Ullrich myopathy. Grosu, Irina; Truong, David; Teodorescu, Simona; Mousny, Maryline; Veyckemans, Francis // Journal of Anesthesia;2012, Vol. 26 Issue 4, p636 

    A letter to the editor is presented about the clinical case of a nine-year-old boy who received anesthesia for Ullrich's myopathy (UD).

  • Correction of Multiple Striated Muscles in Murine Pompe Disease Through Adeno-associated Virus–mediated Gene Therapy. Sun, Baodong; Young, Sarah P.; Li, Ping; Di, Chunhui; Brown, Talmage; Salva, Maja Z.; Li, Songtao; Bird, Andrew; Yan, Zhen; Auten, Richard; Hauschka, Stephen D.; Koeberl, Dwight D. // Molecular Therapy;Aug2008, Vol. 16 Issue 8, p1366 

    Glycogen storage disease type II (Pompe disease; MIM 232300) stems from the deficiency of acid α-glucosidase (GAA; acid maltase; EC 3.2.1.20), which primarily involves cardiac and skeletal muscles. An adeno-associated virus 2/8 (AAV2/8) vector containing the muscle creatine kinase (MCK) (CK1)...

  • Impact of enzyme replacement therapy on survival in adults with Pompe disease: results from a prospective international observational study. Güngör, Deniz; Kruijshaar, Michelle E.; Plug, Iris; D'Agostino Sr., Ralph B.; Hagemans, Marloes L. C.; van Doorn, Pieter A.; Reuser, Arnold J. J.; van der Ploeg, Ans T. // Orphanet Journal of Rare Diseases;2013, Vol. 8 Issue 1, Special section p1 

    Background: Pompe disease is a rare metabolic myopathy for which disease-specific enzyme replacement therapy (ERT) has been available since 2006. ERT has shown efficacy concerning muscle strength and pulmonary function in adult patients. However, no data on the effect of ERT on the survival of...

  • Cessation and resuming of alglucosidase alfa in Pompe disease: a retrospective analysis. Hundsberger, Thomas; Rösler, Kai; Findling, Oliver // Journal of Neurology;Sep2014, Vol. 261 Issue 9, p1684 

    Enzyme replacement therapy (ERT) with recombinant human alglucosidase alfa (rhGAA) in late-onset Pompe disease is moderately effective. Little is known about the clinical course after treatment termination and the resumption of ERT. In Switzerland, rhGAA therapy for Pompe disease was temporarily...

  • If the gene fits, wear it.  // Newsweek;8/30/1993, Vol. 122 Issue 9, p61 

    Discusses research therapy aimed at curing muscular dystrophy (MD). Gene reduction techniques that have been successful in laboratory mice; Hopes that this treatment technique can be adapted to humans.

  • Efficient adenovirus-mediated transfer of a human minidystrophin gene to skeletal muscle of mdx mice Ragot, Thierry; Vincent, Nathalie // Nature;2/18/1993, Vol. 361 Issue 6413, p647 

    Tests the ability of a recombinant adenovirus containing a 6.3 kilobase pair Becker-like dystrophin complementary DNA driven by the Rous sarcoma virus promoter to direct the expression of a `minidystrophin' in infected 293 cells and C2 myoblasts, and in the mdx mouse. Obtaining a sarcolemmal...

  • Skin cells hold promise for wasted muscle. Coghlan, Andy // New Scientist;9/16/95, Vol. 147 Issue 1995, p22 

    Informs medical researchers claim that genetically engineered skin cells that change into muscle cells could treat muscular dystrophy. Pathology and symptoms of muscular dystrophy disease; Comments of Diana Watt of Charing Cross and Westminster School, about the cause of dystrophy disease.

  • Utrophin to the rescue. Campbell, Kevin P.; Crosbie, Rachelle H. // Nature;11/28/1996, Vol. 384 Issue 6607, p308 

    Provides background and analysis for a report that shows that utrophin can effectively rescue dystrophin-deficient muscle in vivo. The study strongly supporting a therapeutic strategy to fight duchenne muscular dystrophy; The strategy involving the upregulation of utrophin; The paper by Kay...

  • Real-life spider men using protein found in venom to develop muscular dystrophy treatment.  // Biomedical Market Newsletter;8/1/2012, Vol. 21, p1 

    The article presents information on the development of the treatment of muscular dystrophy by using the protein found in venom of spiders.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics